Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma
Abstract
Aim: To investigate the effects of residual plasma Epstein-Barr virus (EBV) DNA levels after 3 months of intensity-modulated radiation therapy (IMRT) (postIMRT-EBV DNA) on prognosis in patients with nasopharyngeal carcinoma. Methods: Data from 300 patients were retrospectively collected for analysis. Results: Of these patients, 25 (8.3%) and 275 (91.7%) had positive and negative postIMRT-EBV DNA, respectively. Multivariate survival analysis showed that EBV DNA >688 IU/ml was independently associated with inferior distant metastasis-free survival (p = 0.003) and progression-free survival (p = 0.002). Moreover, postIMRT-EBV DNA was independently associated with inferior locoregional recurrence-free survival (hazard ratio: 4.325; p = 0.018), distant metastasis-free survival (hazard ratio: 10.226; p < 0.001) and progression-free survival (hazard ratio: 10.520; p < 0.001). Conclusion: Positive postIMRT-EBV DNA is a prognostic biomarker for nasopharyngeal carcinoma.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Focus on nasopharyngeal carcinoma. Cancer Cell 5(5), 423–428 (2004).
- 2. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 50(5), 330–338 (2014).
- 3. . Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma. Chin. Clin. Oncol. 5(2), 18 (2016). •• Evaluated the use of Epstein-Barr virus (EBV) DNA in the management of nasopharyngeal carcinoma (NPC).
- 4. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin. Cancer Res. 9(9), 3254–3259 (2003).
- 5. Plasma Epstein-Barr virus DNA screening followed by 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting post-treatment failures of nasopharyngeal carcinoma. Cancer 117(19), 4452–4459 (2011).
- 6. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377(6), 513–522 (2017). • Analyzed EBV DNA to screen for NPC.
- 7. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 60(24), 6878–6881 (2000).
- 8. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of post-therapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98(2), 288–291 (2003). •• Evaluated the use of pretreatment EBV DNA in the prognostic assessment of NPC.
- 9. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl Cancer Inst. 94(21), 1614–1619 (2002). • Evaluated the use of EBV DNA in the prognostic assessment of NPC.
- 10. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med. 350(24), 2461–2470 (2004).
- 11. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 17(11), 1509–1520 (2016).
- 12. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncol. 62, 114–121 (2016).
- 13. Prognostic value of programmed cell death-ligand 1 expression in tumor-infiltrating lymphocytes and viral load in peripheral blood mononuclear cells for Epstein-Barr virus-positive nasopharyngeal carcinoma. Clin. Chem. 66(9), 1219–1227 (2020).
- 14. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122(4), 546–558 (2016).
- 15. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiother. Oncol. 167, 179–186 (2022).
- 16. Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? J. Cancer 8(6), 976–982 (2017).
- 17. Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 104(2), 355–361 (2019). •• Evaluated EBV DNA level after induction chemotherapy in the prognostic assessment of NPC.
- 18. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level. BMC Cancer 20(1), 89 (2020).
- 19. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. Chin. J. Cancer 36(1), 98 (2017).
- 20. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with post radiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int. J. Radiat. Oncol. Biol. Phys. 89(1), 21–29 (2014).
- 21. The value of plasma EBV DNA in monitoring the therapeutic effect of nasopharyngeal carcinoma. Chin. J. Radiat. Oncol. 28(12), 881–884 (2019).
- 22. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 68(5), 1342–1348 (2007).
- 23. Magnetic resonance imaging-detected tumor residue after intensity-modulated radiation therapy and its association with post-radiation plasma Epstein-Barr virus deoxyribonucleic acid in nasopharyngeal carcinoma. J. Cancer 8(5), 861–869 (2017).
- 24. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J. Clin. Oncol. 36(31), 3091–3100 (2018). •• Evaluated treatment for those with EBV DNA-positive disease after concurrent chemoradiotherapy.
- 25. Adjuvant apatinib in nasopharyngeal carcinoma with residual Epstein-Barr virus DNA after radiation therapy: a biomarker-driven, phase 2 trial. Int. J. Radiat. Oncol. Biol. Phys. 113(5), 1063–1071 (2022).
- 26. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 22(8), 1162–1174 (2021).
- 27. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat. Med. 27(9), 1536–1543 (2021).